Table 1. Patient characteristics—numbers of patients (%).
|
Breast |
Colorectal |
Prostate |
||||
|---|---|---|---|---|---|---|
| Characteristic (%) | QOL data | Cost data | QOL data | Cost data | QOL data | Cost data |
| Patients consented | 297 |
192 |
147 |
|||
| Eligible patients | 291 |
164 |
140 |
|||
| Patients analysed | 250 | 223 | 135 | 146 | 130 | 104 |
|
EQ-5D questionnaire returns | ||||||
| 6 months | 231 (92.4) | 128 (94.8) | 126 (96.9) | |||
| 12 months | 186 (74.4) | 101 (74.8) | 109 (83.8) | |||
| 15 months | 177 (70.8) | 97 (71.9) | 106 (81.5) | |||
|
Sex | ||||||
| Male | 1 (0.4) | 2 (0.9) | 86 (63.7) | 89 (61.0) | ||
| Female | 249 (99.6) | 221 (99.1) | 49 (36.3) | 57 (39.0) | ||
|
Age | ||||||
| <65 | 194 (77.6) | 172 (77.1) | 76 (56.3) | 80 (54.8) | 58 (44.6) | 50 (48.1) |
| ⩾65 | 56 (22.4) | 51 (22.9) | 59 (43.7) | 66 (45.2) | 72 (55.4) | 54 (51.9) |
|
IMD | ||||||
| 1 | 48 (19.2) | 47 (21.1) | 25 (18.) | 32 (21.9) | 14 (10.8) | 12 (11.5) |
| 2 | 45 (18.0) | 42 (18.8) | 30 (22.2) | 31 (21.2) | 21 (16.2) | 16 (15.4) |
| 3 | 33 (13.2) | 28 (12.6) | 24 (17.8) | 25 (17.1) | 24 (18.5) | 20 (19.2) |
| 4 | 71 (28.4) | 58 (26.0) | 30 (22.2) | 34 (23.3) | 36 (27.7) | 28 (26.9) |
| 5 | 53 (21.2) | 48 (21.5) | 26 (19.3) | 24 (16.4) | 35 (26.9) | 28 (26.9) |
|
HER2 status | ||||||
| Positive | 13 (5.2) | 17 (7.6) | ||||
| Negative | 138 (55.2) | 158 (70.9) | ||||
| Unknown | 99 (39.6) | 48 (21.5) | ||||
|
Hormone receptor | ||||||
| Positive | 158 (63.2) | 139 (62.3) | ||||
| Negative | 92 (36.8) | 84 (37.7) | ||||
|
Lymph nodes | ||||||
| N0 | 125 (50.0) | 140 (62.8) | ||||
| N positive | 47 (18.8) | 57 (25.6) | ||||
| Unknown | 78 (31.2) | 26 (11.7) | ||||
|
Primary tumour | ||||||
| T1 | 112 (44.8) | 133 (59.6) | ||||
| T2 | 51 (20.4) | 55 (24.7) | ||||
| T3 | 6 (2.4) | 7 (3.1) | ||||
| T4 | 0 (0) | 0 (0) | ||||
| Unknown | 81 (32.4) | 28 (12.6) | ||||
|
Grade | ||||||
| 1 | 43 (17.2) | 51 (22.9) | ||||
| 2 | 106 (42.4) | 95 (42.6) | ||||
| 3 | 56 (22.4) | 53 (23.8) | ||||
| Unknown | 45 (18.0) | 24 (10.8) | ||||
|
Dukes staging | ||||||
| A | 15 (11.1) | 19 (13.0) | ||||
| B | 25 (18.5) | 31 (21.2) | ||||
| C | 19 (14.1) | 26 (17.8) | ||||
| D | 1 (0.7) | 1 (0.7) | ||||
| Unknown | 75 (55.6) | 69 (47.3) | ||||
|
Gleason score | ||||||
| 0–5 | 0 (0) | 0 (0) | ||||
| 6 | 36 (27.7) | 28 (26.9) | ||||
| 7 | 60 (46.2) | 56 (53.8) | ||||
| 8 | 2 (1.5) | 2 (1.9) | ||||
| 9 | 9 (6.9) | 7 (6.7) | ||||
| 10 | 0 (0) | 0 (0) | ||||
| Unknown | 23 (17.7) | 11 (10.6) | ||||
Abbreviations: HER2=human epidermal growth factor receptor 2; IMD=Index of Multiple Deprivation; QoL=quality of life.